Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.

INTRODUCTION: Although mefloquine use is known to be associated with a risk of severe neuropsychiatric adverse reactions that are often preceded by prodromal symptoms, specific combinations of neurologic or psychiatric reactions associated with mefloquine use are not well described in the literature. This study sought to identify a distinct neuropsychiatric syndrome class associated with mefloquine use in reports of adverse events.
METHODS: Latent class modeling of US Food and Drug Administration Adverse Event Reporting System (FAERS) data was performed using indicators defined by the Medical Dictionary for Regulatory Activities neurologic and psychiatric high-level group terms, in a study dataset of FAERS reports (n = 5332) of reactions to common antimalarial drugs.
RESULTS: A distinct neuropsychiatric syndrome class was identified that was strongly and significantly associated with reports of mefloquine use (odds ratio = 3.92, 95% confidence interval 2.91-5.28), defined by a very high probability of symptoms of deliria (82.7%) including confusion and disorientation, and a moderate probability of other severe psychiatric and neurologic symptoms including dementia and amnesia (18.6%) and seizures (18.1%). The syndrome class was also associated with symptoms that are considered prodromal including anxiety, depression, sleep disturbance, and abnormal dreams, and neurological symptoms such as dizziness, vertigo, and paresthesias.
CONCLUSIONS: This study confirms in FAERS reports the existence of a severe mefloquine neuropsychiatric syndrome class associated with common symptoms that may be considered prodromal. Clinical identification of the characteristic symptoms of this syndrome class may aid in improving case finding in pharmacovigilance studies of more serious adverse reactions to the drug.

Key Points

Introduction

Use of mefloquine, a synthetic quinoline derivative antimalarial, has been well known for many decades to be associated with a risk of occasionally severe, neuropsychiatric adverse reactions [1]. When used prophylactically to prevent malaria, certain of these reactions may be considered prodromal, and as described in a recent boxed warning mandated by the US Food and Drug Administration (FDA) in 2013, may predict the development of more serious adverse effects, including potentially disabling psychiatric and neurological symptoms that may persist or become permanent after mefloquine has been discontinued [2, 3].

Symptoms consistent with prodromal reactions to mefloquine, which include very common symptoms of sleep disturbance and abnormal dreams, which are reported in greater than 10% of users, and common symptoms of anxiety and depression, which are reported in between 1 and 10% of users [2], may occur independently in settings such as international travel [4] and military operations [5] where mefloquine may be used prophylactically. Such prodromal reactions may also be plausibly reported as a result of reporting bias, or because of nocebo effects [6]. Certain symptoms consistent with those of the mefloquine prodrome may also occur from other drugs in settings of mefloquine use. For example, two other antimalarial drugs commonly used for prophylaxis of chloroquine-resistant malaria, atovaquone-proguanil and doxycycline, are also associated with symptoms of sleep disturbance and abnormal dreams [7], although these are reported less commonly than with mefloquine [8-10]. Similarly, chloroquine has also long been associated with symptoms similar to those caused by mefloquine [11, 12], although as with atovaquone-proguanil and doxycycline, their occurrence with the use of chloroquine is not accompanied by warnings to discontinue the drug at their onset.

Owing to the perceived ubiquity of such symptoms in settings of mefloquine use, the unique guidance applicable to mefloquine to discontinue the drug at the onset of prodromal symptoms such as sleep disturbance, abnormal dreams, anxiety, and depression may risk being minimized or overlooked [2]. Similarly, as demonstrated by case reports [13-15], such symptoms may be misattributed by the patient or the clinician to causes other than to mefloquine. In each case, this may potentially reduce the effectiveness of regulatory guidance that the drug be discontinued at their onset [2].

While US regulators at the FDA have noted that more serious neurologic reactions to mefloquine are typically accompanied by lasting psychiatric symptoms [3, 16], specific combinations of neurologic and psychiatric reactions associated with mefloquine use are not well described in the literature. The absence in the literature of a well-characterized and specific syndrome of neuropsychiatric adverse reactions associated with mefloquine use may risk such combinations of reactions confounding the diagnosis of numerous other neuropsychiatric disorders [17, 18], which may consequently limit the specificity of case finding in pharmacovigilance studies of adverse reactions.

This study therefore sought to identify a distinct neuropsychiatric syndrome class associated with reports of adverse reactions from mefloquine use. This study further sought to confirm the association of this syndrome with prodromal symptoms, and to identify other specific symptoms commonly associated with it that might inform improvements in case finding.

Methods

Latent class modeling (LCM) is a statistical method enabling the grouping of individuals into one or more distinct classes on the basis of responses to a finite number of indicators, such as the presence or absence of various reported symptoms [19]. LCM is a commonly accepted method for improving accuracy in psychiatric diagnosis in the absence of an objective “gold standard” [20]. Although the reporting of drug adverse reactions may involve selecting from potentially thousands of distinct medical terms, these may be categorized into a manageable number by means of the Medical Dictionary for Regulatory Activities (MedDRA) vocabulary, which translates reported reactions into standard terminology known as lowest level terms, and groups these into medically similar or equivalent preferred terms (PTs) [21]. The MedDRA further categorizes PTs multiaxially into one or more of 26 top-level system organ classes (SOCs), and within each SOC, to typically one of a few dozen distinct high-level group terms (HLGTs) [21], thus making the presence or absence of reactions categorized at the SOC or HLGT level of potential utility as indicators in LCM.

In this analysis, both SOC- and HLGT-level indicators were used in conducting case-level LCM among drug adverse events reported to the FDA. Reports used in this analysis included those for the three antimalarial drugs commonly used in the prophylaxis of chloroquine-resistant malaria, mefloquine, atovaquone-proguanil, and doxycycline; and as controls, those for chloroquine and the anti-motility agent loperamide, a common co-exposure in settings where antimalarials are used [22].

Descriptive statistical analyses were conducted using STATA Version 14 (StataCorp, College Station, TX, USA), and LCM was conducted using MPLUS Version 7.4 (Muthen & Muthen, Los Angeles, CA, USA).

Study Data

Reports of adverse reactions are maintained by the FDA in the FDA Adverse Event Reporting System (FAERS) [23]. Study data were obtained by querying the Qscan FDA database (DrugLogic, Reston, VA, USA), a commercial aggregator of publicly available FAERS data, for all FAERS reports listing mefloquine, atovaquone-proguanil, doxycycline, chloroquine, and loperamide or their common generic and trade variants as suspect or non-suspect drugs through 2012, the year prior to the FDA boxed warning. Duplicate reports based on same age, sex, and FDA receipt dates were automatically excluded from the query.

MedDRA Categorization of FAERS Report Reactions

Where reactions in historical FAERS reports did not match a current MedDRA PT, these were updated to the current MedDRA vocabulary if these matched a current lowest level term, or where there was no match, manually to a lexical variant of a current lowest level term. Where a PT was multiaxial, PT assignment was prioritized to the SOC psychiatric disorders and nervous system disorders, in that order. Categorized reactions of a general, social, or procedural nature (i.e., SOCs general disorders and administration-site conditions; investigations; injury, poisonings, and procedural complications; surgical and medical procedures; and social circumstances) were excluded. Reactions describing congenital and perinatal conditions (i.e., SOCs congenital, familial, and genetic disorders; and pregnancy, puerperium, and perinatal conditions), neoplastic conditions (i.e., SOC neoplasms benign, malignant and unspecified including cysts and polyps), immune and infectious disorders (i.e., SOCs immune system disorders; and infections and infestations), and conditions of the reproductive system (i.e., SOC reproductive system and breast disorders) were also excluded.

For each FAERS report, binary indicators corresponding to the 15 remaining SOCs, and to individual HLGTs within the psychiatric and nervous system disorder SOCs, were created on the basis of reported PTs.

Study Datasets

By drug, datasets were created collapsing by case number any positive response in binary SOC- and HLGT-level indicators across original and subsequent FAERS reports. By case, the minimum of reported age (when not unknown) was assigned as case age; sex was assigned as male, female, or unknown; and for the three primary study drugs mefloquine, atovaquone-proguanil, and doxycycline, the indication was assigned as either for malaria prophylaxis or other/unknown. To exclude neonatal cases potentially due to maternal exposure, cases less than 1 year of age were excluded. Datasets by drug were then pooled, and to ensure independence in subsequent LCM, cases appearing in multiple study drug datasets were excluded. Two study datasets were created from the pooled dataset: the primary dataset consisting of mefloquine, atovaquone-proguanil, and doxycycline cases; and a control dataset consisting of chloroquine and loperamide cases.

Latent Class Indicator Selection

To permit the data-driven selection of specific indicators for the final LCM, initial latent class models were first estimated from SOC-level indicators in the primary dataset with greater than 2% overall prevalence with the aim of identifying broad neuropsychiatric classes of reaction from which specific neuropsychiatric HLGT-level indicators would then be selected.

Two separate models were first estimated to assess for convergent results across models: the first, a fully conditionally dependent (full) model in which conditional dependence was permitted between all indicator pairs; and second, a partially conditionally dependent (partial) model in which conditional dependence was permitted between selected indicator pairs. For the partial model, these were iteratively fit, specifying conditional dependence between SOC-level indicator pairs with significant pairwise bivariate residuals (Pearson χ2 > 1.96), until a final model could be estimated with non-significant pairwise bivariate residuals. Among each model, fit statistics were compared, with the final model selection made based on Bayesian information criteria (BIC) [19]. The partial model was evaluated for evidence of residual conditional dependence by means of multiple, random probability-weighted pseudoclass assignment, whereby SOC-level indicators with Bonferroni-adjusted significant p values from pairwise logistic regression in five or more of 100 draws by pseudoclass were deemed to exhibit significant conditional dependence.

From each selected model, multiple neuropsychiatric classes were then identified based on relatively elevated conditional probabilities for psychiatric and nervous system disorder SOC-level indicators. Among cases with the most-likely membership in the identified neuropsychiatric classes, neuropsychiatric HLGT-level indicators were then similarly evaluated for evidence of differential measurement by drug by means of multiple, random probability-weighted pseudoclass assignment [24]. HLGT-level indicators free of evidence of significant differential measurement across model neuropsychiatric classes, and with greater than 2% overall prevalence, were considered for selection for the final LCM.

HLGT-Level LCM

Latent class models with two through four classes were estimated from the primary dataset from the selected neuropsychiatric HLGT-level indicators, permitting pairwise conditional dependence between all indicators, with the final model selection made based on BIC. To account for uncertainty in class membership, association of HLGT-level class with drug was assessed by corrected three-step testing in MPLUS, per published methods [25] with results reported as odds ratios (ORs) and 95% confidence intervals (95% CIs).

Results

The number of cases by drug and final dataset are shown in Fig. 1. When pooled, 196 of the 12,674 cases (1.5%) were excluded for listing multiple study drugs. The sex and age group of study cases by drug are shown in Table 1. The age and sex distribution of cases varied significantly by χ2 test by drug for age group (p < 0.001) and for sex (p < 0.001) in both the primary dataset and the pooled data overall. In the primary dataset, the distribution of reported indication also varied significantly by χ2 test by drug (p < 0.001), as shown in Table 2.

Fig. 1

Study cases in the primary and control datasets. AP atovaquone-proguanil, CQ chloroquine, DX doxycycline, LP loperamide, MQ mefloquine

Table 1

Sex and age groups of study cases in the primary and control datasets, by drug

	Primary dataset			Control dataset
	Mefloquine	Atovaquine-proguanil	Doxycycline	Chloroquine	Loperamide
	n (%)	n (%)	n (%)	n (%)	n (%)
All cases	933 (100)	450 (100)	3949 (100)	422 (100)	6724 (100)
Sex
Male	489 (52.4)	198 (44.0)	1506 (38.1)	109 (25.8)	3306 (49.2)
Female	418 (44.8)	224 (49.8)	2308 (58.5)	300 (71.1)	3194 (47.5)
Unknown	26 (2.8)	28 (6.2)	135 (3.4)	13 (3.1)	224 (3.3)
Age group, years
<18	51 (5.5)	35 (7.8)	192 (4.9)	22 (5.2)	181 (2.7)
18–65	595 (63.8)	225 (50)	1917 (48.5)	216 (51.2)	2659 (39.5)
65+	287 (30.8)	190 (42.2)	1840 (46.6)	184 (43.6)	3884 (57.8)

Across all strata, proportions varied significantly by drug, in both the primary dataset and in the pooled data overall (p < 0.05 by χ2 test)

Table 2

Drug indication of study cases in the primary dataset, by drug

	Primary dataset
	Mefloquine	Atovaquone-proguanil	Doxycycline
	n (%)	n (%)	n (%)
All cases	933 (100)	450 (100)	3949 (100)
Drug indication
Malaria prophylaxis	294 (31.5)	278 (61.8)	30 (0.8)
Other or unknown	639 (65.5)	172 (38.2)	3,919 (99.2)

Proportions varied significantly by drug (p < 0.001 by χ2 test)

SOC-Level Modeling

Total numbers and proportions of cases with reported reactions in each of the 15 study SOCs were tabulated by drug in the primary dataset and are shown in Table 3. The proportions of reported reactions varied significantly by χ2 test by drug across all SOCs (all p < 0.05). By drug, the most commonly reported reactions were within the psychiatric disorders SOC for mefloquine (56.5% of cases, most commonly the PT anxiety), the nervous system disorders SOC for atovaquone-proguanil (29.1% of cases, most commonly the PT headache), and the gastrointestinal disorders SOC for doxycycline (31.4% of cases, most commonly the PT nausea). Reactions were reported in fewer than 2% of cases overall within two SOCs, ear and labyrinth disorders, and endocrine disorders, which were excluded from subsequent LCM.

Table 3

Prevalence of reported reactions by MedDRA SOC, by drug and overall, primary dataset

	Mefloquine	Atovaquone-proguanil	Doxycycline	Overall
	n (%)	n (%)	n (%)	n (%)
Any SOC	933 (100)	450 (100)	3949 (100)	5332 (100)
Blood and lymphatic system disorders	55 (5.6)	42 (9.3)	487 (12.3)	584 (11.0)
Cardiac disorders	136 (14.6)	19 (4.2)	473 (12.0)	628 (11.8)
Ear and labyrinth disordersa	33 (3.5)	6 (1.3)	70 (1.8)	109 (2.0)
Endocrine disordersa	7 (0.8)	2 (0.4)	70 (1.8)	79 (1.5)
Eye disorders	67 (7.2)	25 (5.6)	212 (5.4)	304 (5.7)
Gastrointestinal disorders	233 (25.0)	123 (27.3)	1242 (31.4)	1598 (30.0)
Hepatobiliary disorders	36 (3.9)	26 (5.8)	326 (8.3)	388 (7.3)
Metabolism and nutrition disorders	67 (7.2)	33 (7.3)	447 (11.3)	547 (10.3)
Musculoskeletal and connective tissue disorders	117 (12.5)	33 (7.3)	614 (15.6)	764 (14.3)
Nervous system disorders	438 (47.0)	131 (29.1)	1193 (30.2)	1762 (33.0)
Psychiatric disorders	527 (56.5)	95 (21.1)	805 (20.4)	1427 (26.8)
Renal and urinary disorders	41 (4.4)	20 (4.4)	381 (9.6)	442 (8.3)
Respiratory, thoracic, and mediastinal disorders	127 (13.6)	45 (10.0)	767 (19.4)	939 (17.6)
Skin and subcutaneous tissue disorders	148 (15.9)	106 (23.6)	790 (20.0)	1044 (19.6)
Vascular disorders	66 (7.1)	26 (5.8)	618 (15.6)	710 (13.3)

MedDRA Medical Dictionary for Regulatory Activities, SOC system organ class

Across all SOCs, proportions varied significantly by drug (p < 0.05 by χ2 test)

aSOC with 2.0% prevalence or less overall excluded from subsequent SOC-level analysis

In the primary dataset, reactions within the nervous system disorder SOC were reported for 20 HLGTs at frequencies ranging from 0.03 to 22.2%, and within the psychiatric disorder SOC for 23 HLGTs at frequencies ranging from 1.1 to 12.6%.

In the SOC-level LCM, full models with two through five classes had BIC of 54,213, 54,162, 54,158, and 54,193; and partial models with two through seven classes had BIC of 54,006, 53,994, 53,967, 53,965, 53,937, and 53,940, respectively. The four-class full and six-class partial models were selected based on the best fit by BIC. Class labels were assigned subjectively based on conditional probabilities, with a mild and moderate neuropsychiatric class identified in each, as shown in Fig. 2.

Fig. 2

Conditional probabilities, SOC-level models. a Fully conditionally dependent (full) model. b Partially conditionally dependent (partial) model. blood blood and lymphatic system disorders, cardiac cardiac disorders, derm skin and subcutaneous tissue disorders, eye eye disorders, gastro gastrointestinal disorders, hep hepatobiliary disorders, metab metabolism and nutrition disorders, ms musculoskeletal and connective tissue disorders, neuro nervous system disorders, psych psychiatric disorders, renal renal and urinary disorders, resp respiratory, thoracic, and mediastinal disorders, vascular vascular disorders. Line thickness is proportional to class membership conditional probability. SOC system organ class

The partial model had entropy of 0.560 and a non-significant overall univariate residual (χ2 = 0.003, p > 0.05). Despite non-significant pairwise bivariate residuals (χ2 < 1.96, p > 0.05 for all comparisons), the overall bivariate residual was significant (χ2 = 13.79, p > 0.05), with evidence on subsequent pseudoclass testing of significant residual conditional dependence between indicator pairs for the respiratory and vascular SOCs, and for the hepatobiliary and metabolic SOCs in the moderate neuropsychiatric class; and between indicator pairs for the cardiac and renal SOCs in the multi-system class. In contrast, the full model had entropy of 0.872, and non-significant overall univariate and bivariate as well as pairwise bivariate residuals.

HLGT-Level Modeling

Assigning subjects to their most-likely class, prevalence of reported reactions by HLGT in both the moderate and mild neuropsychiatric classes, in the partial and full models, by most-likely class and overall without regard to class assignment, is shown in Table 4. Of the 42 neuropsychiatric HLGTs, anxiety disorders and symptoms, sleep disorders and disturbances, and neurological disorders not elsewhere classified (NEC) were most prevalent across model classes, but these HLGTs and nine others had evidence of significant differential measurement across both the mild and moderate neuropsychiatric classes in both the full and partial models and were excluded from further consideration. Of the remaining 30, eight occurred at 2% prevalence or greater and exhibited no significant differential measurement in the moderate neuropsychiatric class in both the full and partial models, and these were selected as indicators for the final LCM. HLGTs selected for the final model included communication disorders and disturbances; deliria (including confusion); dementia and amnestic conditions; depressed mood disorders and disturbances; neuromuscular disorders; peripheral neuropathies; psychiatric disorders NEC; and seizures (including subtypes).

Table 4

Prevalence of reported reactions by MedDRA neuropsychiatric HLGT, by SOC-level latent class model most-likely neuropsychiatric class, and overall

	Moderate		Mild		Overall
	Partial	Full	Partial	Full
	n (%)	n (%)	n (%)	n (%)	n (%)
Any neuropsychiatric HLGT	511 (93.4)	465 (92.0)	1577 (89.6)	1878 (43.0)	2429 (45.6)
Adjustment disorders (including subtypes)	2a (0.4)	2a (0.43)	4a (0.2)	3a (0.1)	11 (0.21)
Anxiety disorders and symptoms	145a (28.4)	149a (32.0)	369a (20.1)	379a (8.7)	604 (11.3)
Changes in physical activity	15a (2.9)	18a (3.9)	40a (2.3)	38a (0.9)	67 (1.3)
CNS infections	11 (2.2)	9 (1.9)	18 (1.0)	23 (0.5)	39 (0.7)
CNS vascular disorders	29 (5.7)	24a (5.2)	68 (3.9)	81 (1.9)	134 (2.5)
Cognitive and attention disorders and disturbances	45a (8.8)	46a (9.9)	103a (5.8)	102a (2.3)	171 (3.2)
Communication disorders and disturbancesb	31 (6.1)	34 (7.3)	75 (4.3)	73 (1.7)	126 (2.4)
Congenital neurological disorders	3 (0.6)	3 (0.6)	3 (0.2)	3 (0.1)	8 (0.2)
Cranial nerve disorders (excluding neoplasms)	35a (6.8)	35a (7.5)	99a (5.6)	109a (2.5)	167 (3.1)
Deliria (including confusion) b	60 (11.7)	55 (11.8)	128a (7.3)	135a (3.1)	219 (4.1)
Dementia and amnestic conditionsb	37 (7.2)	42 (9.0)	92a (5.2)	92a (2.1)	161 (3.0)
Demyelinating disorders	5 (1.0)	2 (0.4)	19 (1.1)	26 (0.6)	32 (0.6)
Depressed mood disorders and disturbancesb	89 (17.4)	85 (18.3)	184a (10.4)	192a (4.4)	340 (6.4)
Developmental disorders NEC	0 (0.0)	0 (0.0)	1 (0.1)	1 (0.0)	1 (0.0)
Dissociative disorders	6 (1.2)	6 (1.3)	16a (0.9)	16a (0.4)	25 (0.5)
Disturbances in thinking and perception	41a (8.0)	43a (9.2)	176a (10.0)	179a (4.1)	242 (4.5)
Eating disorders and disturbances	29 (5.7)	25 (5.4)	31 (1.8)	36 (0.8)	73 (1.4)
Encephalopathies	15 (2.9)	16 (3.4)	16 (0.9)	20 (0.5)	43 (0.8)
Headaches	131a (25.6)	121a (26.0)	190 (10.8)	242a (5.6)	415 (7.8)
Impulse control disorders NEC	2 (0.4)	2 (0.4)	12 (0.7)	12 (0.3)	16 (0.3)
Increased intracranial pressure	11 (2.2)	9 (1.9)	50 (2.8)	54 (1.2)	70 (1.3)
Manic and bipolar mood disorders	7 (1.4)	10 (2.2)	40a (2.3)	40a (0.9)	55 (1.0)
Mood disorders and disturbances NEC	73a (14.3)	74a (15.9)	193a (11.0)	203a (4.6)	318 (6.0)
Movement disorders (including parkinsonism)	61a (11.9)	62a (13.3)	127 (7.2)	141a (3.2)	230 (4.3)
Nervous system neoplasms benign	0 (0.0)	1 (0.2)	2 (0.1)	2 (0.0)	4 (0.1)
Nervous system neoplasms malignant	0 (0.0)	0 (0.0)	2 (0.1)	3 (0.1)	6 (0.1)
Neurological disorders of the eye	47a (9.2)	39a (8.4)	112 (6.4)	130a (3.0)	204 (3.8)
Neurological disorders NEC	268a (52.4)	253a (54.4)	582a (33.0)	736a (16.9)	1089 (20.4)
Neuromuscular disordersb	43 (8.4)	40 (8.6)	67 (3.8)	82a (1.9)	163 (3.1)
Peripheral neuropathiesb	30 (5.9)	28 (6.0)	32 (1.8)	44 (1.0)	116 (2.2)
Personality disorders and disturbances	20a (3.9)	27a (5.8)	153a (8.7)	149a (3.4)	188 (3.5)
Psychiatric and behavioral symptoms	26a (5.1)	30 (6.4)	77a (4.4)	76a (1.7)	119 (2.2)
Psychiatric disorders NECb	47 (9.2)	44 (9.5)	71 (4.0)	74a (1.7)	148 (2.8)
Schizophrenia and other psychotic disorders	17a (3.3)	13a (2.8)	82a (4.7)	85a (2.0)	109 (2.0)
Seizures (including subtypes) b	40 (7.8)	37 (8.0)	136 (7.7)	151 (3.5)	203 (3.8)
Sexual dysfunctions and disturbances	13 (2.5)	11 (2.4)	18 (1.0)	19 (0.4)	46 (0.9)
Sleep disorders and disturbances	119a (23.3)	113a (24.3)	273a (15.5)	291a (6.7)	454 (8.5)
Sleep disturbances (including subtypes)c	0 (0.0)	0 (0.0)	1 (0.1)	1 (0.0)	1 (0.0)
Somatoform and factitious disorders	20 (3.9)	19 (4.1)	16 (0.9)	15 (0.3)	48 (0.9)
Spinal cord and nerve root disorders	16 (3.1)	13 (2.8)	7 (0.4)	10 (0.2)	57 (1.1)
Structural brain disorders	8 (1.6)	4 (0.9)	10 (0.6)	12 (0.3)	34 (0.6)
Suicidal and self-injurious behavior	37a (7.2)	34a (7.3)	167a (9.5)	169a (3.9)	221 (4.1)

CNS central nervous system, HLGT high-level group term, MedDRA Medical Dictionary for Regulatory Activities, NEC not elsewhere classified, SOC system organ class

aHLGT-level indicators with evidence of significant differential measurement by drug in the model class

bHLGT-level indicator selected for the final model

cIncludes only those reactions not primarily categorized in the psychiatric disorders SOC

In the HLGT-level LCM, models with two through four classes had BIC of 11,908, 11,972, and 12,038, respectively. The two-class model was selected, and had entropy of 0.971, and non-significant overall univariate and bivariate as well as pairwise bivariate residuals. A neuropsychiatric syndrome class with an overall prevalence of 4.3% was identified without evidence of significant differential measurement by drug for any HLGT-level indicator. In contrast, the non-syndrome class demonstrated evidence of significant differential measurement for three HLGT-level indicators: deliria (including confusion), dementia and amnestic conditions, and depressed mood disorders and disturbances. Among cases in the most-likely non-syndrome class, simple logistic regression showed these indicators were significantly more likely to be reported with mefloquine, and significantly less likely to be reported with doxycycline. Conditional probabilities of HLGT-level indicators for the syndrome and non-syndrome class are reported in Table 5.

Table 5

Conditional probabilities by class, two-class HLGT-level latent class model

	Syndrome	Non-syndrome
Communication disorders and disturbances	0.182	0.017
Deliria (including confusion)	0.827	0.006
Dementia and amnestic conditions	0.186	0.023
Depressed mood disorders and disturbances	0.318	0.052
Neuromuscular disorders	0.090	0.028
Peripheral neuropathies	0.082	0.019
Psychiatric disorders NEC	0.314	0.015
Seizures (including subtypes)	0.181	0.032

HLGT high-level group term, NEC not elsewhere classified

Based on the most-likely class assignment, the prevalence of the syndrome class in the primary study dataset was 10.3% with mefloquine, 2.0% with atovaquone-proguanil, and 3.5% with doxycycline. On three-step testing, the syndrome class was positively associated with mefloquine (OR 3.92, 95% CI 2.91–5.28, p < 0.001), and negatively associated with atovaquone-proguanil (OR 0.35, 95% CI 0.14–0.85, p = 0.020) and doxycycline (OR 0.38, 95% CI 0.28–.51, p < 0.001). Applying the fitted model to the control dataset, based on the most-likely class assignment, the prevalence of the syndrome was 3.3% with chloroquine and 6.0% with loperamide. However, on three-step testing, there was no significant association of the syndrome with chloroquine (OR = 0.46, 95% CI 0.17–1.28, p = 0.138) or with loperamide (OR = 2.172, 95% CI 0.78–6.04, p = 0.138).

Most-Likely Class Modeling

On post-hoc analysis of the study dataset, assigning cases to their most-likely class, among the 5095 cases assigned to the non-syndrome class, the five most commonly reported HLGTs across all 15 study SOCs were gastrointestinal signs and symptoms; neurological disorders NEC; epidermal and dermal conditions; respiratory disorders NEC; and anxiety disorders and symptoms. In contrast, among the 237 cases assigned to the most-likely syndrome class, the five most commonly reported HLGTs were deliria (including confusion); neurological disorders NEC; anxiety disorders and symptoms; sleep disorders and disturbances; and depressed mood disorders and disturbances. The prevalence of these most commonly reported syndrome HLGTs together with the most commonly reported reactions, by PT, within each (with greater than 5% overall prevalence), by most-likely class, are listed in Table 6, along with ORs for reporting each HLGT in the most-likely syndrome vs. non-syndrome class.

Table 6

Prevalence of most commonly reported HLGTs and reactions within each, by PT, among cases assigned to most-likely syndrome class, two-class HLGT-level latent class model, by class

	Syndrome	Non-syndrome
	n (%)	n (%)	OR (95% CI)
All cases	237 (100)	5095 (100)
Deliria (including confusion)	181 (76.4)	16 (0.3)	1039.2 (582.1–1855.4)
Confusional state	114 (48.1)	11 (0.2)
Disorientation	55 (23.2)	5 (0.1)
Delirium	25 (10.5)	0 (0.0)
Neurological disorders NEC	109 (46.0)	821 (16.1)	4.3 (3.3–5.6)
Dizziness	41 (17.3)	234 (4.6)
Hypoesthesia	17 (7.2)	128 (2.5)
Paresthesia	16 (6.8)	93 (1.8)
Vertigo	15 (6.3)	52 (1.0)
Anxiety disorders and symptoms	98 (41.4)	412 (8.1)	7.7 (5.8–10.2)
Anxiety	55 (23.2)	245 (4.8)
Agitation	34 (14.3)	50 (1.0)
Panic attack	26 (11.0)	101 (2.0)
Sleep disorders and disturbances	84 (35.4)	318 (6.2)	7.9 (5.9–10.6)
Insomnia	39 (16.5)	147 (2.9)
Somnolence	21 (8.9)	47 (0.9)
Abnormal dreams	19 (8.0)	50 (1.0)
Nightmare	18 (7.6)	65 (1.3)
Sleep disorder	16 (6.8)	26 (0.5)
Depressed mood disturbances and disorders	74 (31.2)	238 (4.7)	8.9 (6.6–12.1)
Depression	62 (26.2)	185 (3.6)

CI confidence interval, HLGT high-level group term, NEC not elsewhere classified, OR odds ratio, PT preferred term

Among the study dataset, among cases assigned to the most-likely class, the proportion of cases by drug in the syndrome class did not vary significantly by χ2 test by age group (<18 years, 18–65 years, and 65+ years) for mefloquine (p = 0.292), atovaquone-proguanil (p = 0.073), or doxycycline (p = 0.151). In contrast, while the proportion of cases in the syndrome class by drug did not vary significantly by χ2 test by sex for atovaquone-proguanil (p = 0.184), they did vary significantly by sex for mefloquine (p = 0.001) and doxycycline (p = 0.002), being strongly associated in each with male sex by simple logistic regression (OR 2.15, 95% CI 1.37–3.38, and OR 1.70, 95% CI 1.20–2.41, respectively).

The proportion of cases by drug in the syndrome class also varied significantly by χ2 test by reported indication for mefloquine (p < 0.001), being strongly associated with malaria prophylaxis (OR 2.29, 95% CI 1.50–3.51) by the most-likely syndrome class assignment, an association not seen with atovaquone-proguanil (p = 0.318) or, by Fischer’s exact test, with doxycycline (p = 0.426). Overall, based on the most-likely class assignment, the prevalence of the syndrome class in the primary study dataset among cases with a reported indication of malaria prophylaxis was 16.0% with mefloquine, 2.5% with atovaquone-proguanil, and 0% with doxycycline.

Discussion

This analysis has found, among reports of adverse events associated with common antimalarial drugs, evidence of a distinct neuropsychiatric syndrome class that is strongly associated with mefloquine use. This syndrome class is defined by a very high probability (82.7%) of symptoms of deliria, including confusion and disorientation, and a moderate probability of other serious psychiatric and neurologic symptoms including dementia and amnestic conditions (18.6%), and seizures (18.1%). Among reports of adverse events associated with drugs used for the prophylaxis of chloroquine-resistant malaria, this syndrome class is nearly exclusive to the use of mefloquine, and occurs in approximately one in six such reports.

Intriguingly, the characteristic symptoms of this syndrome class, including confusion, amnesia, and seizure, were among the earliest reported, serious adverse neuropsychiatric effects of mefloquine noted in the literature following the drug’s initial European licensing in the mid-1980s. Initial case reports described a syndrome of acute brain or toxic encephalopathy, typically with confusion and seizure [26-28]. Isolated amnesia was also reported [29], as was psychosis associated with symptoms of confusion [30]. An early case series, which emphasized neurological reactions, also noted that difficulties with concentration were a common feature [31]. Unlike other possibly more subjective neuropsychiatric symptoms, these severe neuropsychiatric reactions, suggestive of organic central nervous system dysfunction, would be expected to have been subject to minimal reporting bias or nocebo effect.

In this study, among reports of adverse events, this syndrome is commonly accompanied by clinical features that are considered prodromal when associated with mefloquine use, including sleep disturbance, abnormal dreams, anxiety, and depression, as well as neurological symptoms such as dizziness, vertigo, and paresthesias [2]. While this study’s methods could not determine whether any of these reported symptoms preceded the more serious characteristic symptoms of this syndrome class, such progression would be consistent with case reports [13-15] and regulatory warnings describing certain neuropsychiatric symptoms as prodromal to more serious events from the use of mefloquine. Similarly, while this study’s methods could not determine the chronicity of these symptoms, their persistence would be consistent with the results of a recent cohort study of reported mefloquine adverse events, which found symptoms including mood disturbance, cognitive dysfunction, and nightmares occasionally persisting for months to years after the initial adverse event report [32].

Interestingly, this study found that this syndrome class is more common among reports of adverse events from male users than female users of mefloquine. This contrasts with other published findings, in which milder neuropsychiatric symptoms, some of which might be considered prodromal, are more commonly reported among female users of the drug [33, 34]. While the reasons for this are unclear, it is plausible that this finding could reflect a greater propensity among certain male individuals, such as military personnel, to fail to discontinue mefloquine at the onset of prodromal symptoms [11], consequently risking the development of more serious neuropsychiatric effects [2].

Limitations

This study has several important limitations that require the results to be interpreted with caution. This study relied on reported drug adverse event data within the FAERS database, which is known to suffer from significantly incomplete reporting [35, 36], and the accuracy of these data, including suspect drug elements, is often questionable [35]. Partially to address the potential for suspect drug misattribution, this study included reports in the analysis even when the drug was listed as non-suspect. This had the benefit of significantly increasing the sample size, but possibly as a consequence, there were a high number of cases of the neuropsychiatric syndrome class associated with both doxycycline and loperamide. In contrast, in the post-hoc analysis of the study dataset, based on most-likely class assignment, there were no cases of the syndrome class among those in whom doxycycline was reported as indicated for malaria prophylaxis.

This study employed highly conservative methods for identifying residual conditional dependence in the partial model, as well as differential measurement in the SOC- and HLGT-level models. While this was done for computational simplicity, it may have had the effect of over-identification. Additionally, such methods, intended to exclude from the final LCM those HLGT-level indicators with any evidence of differential measurement by drug, essentially excluded from the syndrome class any reactions that might be uniquely associated with mefloquine use. While these methods were deemed desirable to guard against the risk that over-reporting of certain symptoms, such as from a nocebo effect with mefloquine use, would affect the validity of the results, this had the consequence that certain more serious reactions associated with mefloquine in later case reports, such as psychosis [14, 15], were not included among the characteristic features of the syndrome. Additionally, we did not specifically assess for evidence of differential measurement by age, sex, or drug indication, which may limit the validity of inference on these covariates.

Despite these limitations, these results are nonetheless useful and intriguing, and suggest that case finding for more serious neuropsychiatric reactions to mefloquine may be improved through the identification of characteristic reactions that are highly specific to the identified syndrome class. In this respect, it is noteworthy that 181 of the 197 cases (91.9%) in the study dataset reporting one or more reactions within the HLGT that included the PTs confusional state, disorientation, and delirium, were assigned by the model to the most-likely syndrome class, and that this association was exceedingly strong and significant (OR = 1039.2, 95% CI 581.1–1855.4, p < 0.001). These results suggest that among those users reporting adverse neuropsychiatric reactions to common antimalarial medications, and for whom no other likely cause, such as concussion, may be identified for these symptoms, such reactions should be considered nearly pathognomonic for this syndrome class.

Conclusions

Early reports of adverse effects from mefloquine described a clinical syndrome characterized principally by confusion, amnesia, and seizure. This analysis has found evidence of a similar syndrome class in subsequent reports of adverse events from common antimalarial drugs within the FAERS database. This syndrome class is strongly and significantly associated with mefloquine use, particularly in prophylaxis, and is not strongly associated with reports from other common antimalarial drugs when used in the prophylaxis and treatment of chloroquine-resistant malaria. The association of this specific and severe syndrome class with common symptoms that are considered prodromal, including anxiety, depression, sleep disturbance, and abnormal dreams, should reinforce existing regulatory guidance that the drug should be discontinued at their onset. The clinical identification of additional features associated with this syndrome class, including neurological symptoms such as dizziness, vertigo, and paresthesias, may aid in improving case finding in pharmacovigilance studies of more serious adverse reactions to the drug.

Some reports of adverse effects from mefloquine define a syndrome class characterized by symptoms of deliria.

This syndrome class is associated with additional symptoms including some that may be prodromal.